Single-cell heterogeneity in Sézary syndrome

Krejsgaard, 2017, Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover, Semin Immunopathol, 39, 269, 10.1007/s00281-016-0594-9 Agar, 2010, Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal, J Clin Oncol, 28, 4730, 10.1200/JCO.2009.27.7665 Duvic, 2007, Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL), Blood, 109, 31, 10.1182/blood-2006-06-025999 Piekarz, 2009, Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma, J Clin Oncol, 27, 5410, 10.1200/JCO.2008.21.6150 Wilcox, 2016, Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management, Am J Hematol, 91, 151, 10.1002/ajh.24233 Janiga, 2018, Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome, Leuk Lymphoma, 59, 562, 10.1080/10428194.2017.1347650 da Silva Almeida, 2015, The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome, Nat Genet, 47, 1465, 10.1038/ng.3442 Choi, 2015, Genomic landscape of cutaneous T cell lymphoma, Nat Genet, 47, 1011, 10.1038/ng.3356 Ungewickell, 2015, Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2, Nat Genet, 47, 1056, 10.1038/ng.3370 Fanok, 2018, Role of dysregulated cytokine signaling and bacterial triggers in the pathogenesis of cutaneous T-cell lymphoma, J Invest Dermatol, 138, 1116, 10.1016/j.jid.2017.10.028 Weed, 2017, FISH panel for leukemic CTCL, J Invest Dermatol, 137, 751, 10.1016/j.jid.2016.10.037 Gibson, 2016, Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction, J Am Acad Dermatol, 74, 870, 10.1016/j.jaad.2015.12.018 Willemze, 2005, WHO-EORTC classification for cutaneous lymphomas, Blood, 105, 3768, 10.1182/blood-2004-09-3502 Campbell, 2010, Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors, Blood, 116, 767, 10.1182/blood-2009-11-251926 Moins-Teisserenc, 2015, CD158k is a reliable marker for diagnosis of Sézary syndrome and reveals an unprecedented heterogeneity of circulating malignant cells, J Invest Dermatol, 135, 247, 10.1038/jid.2014.356 Roelens, 2017, Circulating and skin-derived Sézary cells: clonal but with phenotypic plasticity, Blood, 130, 1468, 10.1182/blood-2017-03-772996 Kirsch, 2015, TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL, Sci Transl Med, 7, 308ra158, 10.1126/scitranslmed.aaa9122 Buus, 2017, Three distinct developmental pathways for adaptive and two IFN-γ-producing γδ T subsets in adult thymus, Nat Commun, 8, 1911, 10.1038/s41467-017-01963-w Love, 2014, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol, 15, 550, 10.1186/s13059-014-0550-8 Hahne, 2009, flowCore: a Bioconductor package for high throughput flow cytometry, BMC Bioinformatics, 10, 106, 10.1186/1471-2105-10-106 Chen, 2016, Cytofkit: a bioconductor package for an integrated mass cytometry data analysis pipeline, PLOS Comput Biol, 12, e1005112, 10.1371/journal.pcbi.1005112 Morice, 2006, A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sézary syndrome, Am J Clin Pathol, 125, 364, 10.1309/25E9Y7RRAY84HTAT Litvinov, 2017, Gene expression analysis in cutaneous T-cell lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators, OncoImmunology, 6, e1306618, 10.1080/2162402X.2017.1306618 Marusyk, 2012, Intra-tumour heterogeneity: a looking glass for cancer?, Nat Rev Cancer, 12, 323, 10.1038/nrc3261 Qian, 2017, Detection of single cell heterogeneity in cancer, Semin Cell Dev Biol, 64, 143, 10.1016/j.semcdb.2016.09.003 Scala, 2002, T cell receptor-Vbeta analysis identifies a dominant CD60+ CD26- CD49d- T cell clone in the peripheral blood of Sézary syndrome patients, J Invest Dermatol, 119, 193, 10.1046/j.1523-1747.2002.18194.x Scala, 2010, The role of 9-O-acetylated ganglioside D3 (CD60) and alpha4beta1 (CD49d) expression in predicting the survival of patients with Sezary syndrome, Haematologica, 95, 1905, 10.3324/haematol.2010.026260 Bernengo, 2001, The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells, Br J Dermatol, 144, 125, 10.1046/j.1365-2133.2001.04014.x Harmon, 1996, Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses, J Am Acad Dermatol, 35, 404, 10.1016/S0190-9622(96)90605-2 Benoit, 2017, CD164 identifies CD4+ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214, Arch Dermatol Res, 309, 11, 10.1007/s00403-016-1698-8 Clark, 2011, High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma, Blood, 117, 1966, 10.1182/blood-2010-05-287664 Narducci, 2006, Skin homing of Sézary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV, Blood, 107, 1108, 10.1182/blood-2005-04-1492 Kremer, 2017, TCR-CXCR4 signaling stabilizes cytokine mRNA transcripts via a PREX1-Rac1 pathway: implications for CTCL, Blood, 130, 982, 10.1182/blood-2017-03-770982 Foss, 1994, Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sézary syndrome, J Clin Oncol, 12, 326, 10.1200/JCO.1994.12.2.326 Hahtola, 2006, Th1 response and cytotoxicity genes are down-regulated in cutaneous T-cell lymphoma, Clin Cancer Res, 12, 4812, 10.1158/1078-0432.CCR-06-0532 Bresnick, 2015, S100 proteins in cancer, Nat Rev Cancer, 15, 96, 10.1038/nrc3893 Qu, 2017, Chromatin accessibility landscape of cutaneous t cell lymphoma and dynamic response to HDAC inhibitors, Cancer Cell, 32, 27, 10.1016/j.ccell.2017.05.008 Chakraborty, 2013, MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor, Blood, 121, 4115, 10.1182/blood-2012-08-449140 Fantin, 2008, Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma, Cancer Res, 68, 3785, 10.1158/0008-5472.CAN-07-6091